- Home
- ONMD vs EQ Comparison
ONMD vs EQ Comparison
Compare ONMD & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- EQ
- Stock Information
- Founded
- ONMD 2006
- EQ 2017
- Country
- ONMD United States
- EQ United States
- Employees
- ONMD N/A
- EQ N/A
- Industry
- ONMD
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- ONMD
- EQ Health Care
- Exchange
- ONMD Nasdaq
- EQ Nasdaq
- Market Cap
- ONMD 12.8M
- EQ 12.2M
- IPO Year
- ONMD N/A
- EQ 2018
- Fundamental
- Price
- ONMD $0.56
- EQ $0.32
- Analyst Decision
- ONMD
- EQ Buy
- Analyst Count
- ONMD 0
- EQ 3
- Target Price
- ONMD N/A
- EQ $3.00
- AVG Volume (30 Days)
- ONMD 25.4M
- EQ 1.8M
- Earning Date
- ONMD 05-14-2025
- EQ 08-07-2025
- Dividend Yield
- ONMD N/A
- EQ N/A
- EPS Growth
- ONMD N/A
- EQ N/A
- EPS
- ONMD N/A
- EQ N/A
- Revenue
- ONMD $532,000.00
- EQ $30,406,000.00
- Revenue This Year
- ONMD N/A
- EQ N/A
- Revenue Next Year
- ONMD N/A
- EQ N/A
- P/E Ratio
- ONMD N/A
- EQ N/A
- Revenue Growth
- ONMD N/A
- EQ N/A
- 52 Week Low
- ONMD $0.30
- EQ $0.27
- 52 Week High
- ONMD $1.60
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- ONMD 56.14
- EQ 43.51
- Support Level
- ONMD $0.34
- EQ $0.27
- Resistance Level
- ONMD $0.66
- EQ $0.36
- Average True Range (ATR)
- ONMD 0.09
- EQ 0.04
- MACD
- ONMD 0.02
- EQ 0.00
- Stochastic Oscillator
- ONMD 40.17
- EQ 56.67
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its innovative solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols and paves the way for Real World Evidence.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.